论文部分内容阅读
目的评价AML-XH-99-M3方案治疗儿童急性早幼粒细胞白血病(M3)疗效。方法33例M3患儿接受AML-XH-99-M3方案治疗,应用Kaplan-Meier方法进行生存分析,评估患儿的无事生存期(EFS)、无疾病生存期(DFS)及总生存期(OS),所有数据采用SPSS13.0软件统计。结果33例患儿30例(90.9%)一个疗程达完全缓解(CR),余3例二个疗程CR,总CR率为100%,复发6例(18.2%),平均复发时间为29(16～38)个月,死亡2例(6.1%),7年EFS和DFS均为(73.4±9.4)%,总OS为(91.2±6.0)%,维持治疗中间歇加用全反式维甲酸(ATRA)和无ATRA两组EFS差异有统计学意义,分别为(88.9±10.5)%和(62.5±13.6)%(P<0.05)。结论AML-XH-99-M3方案治疗儿童M3获得了很好的CR率,具有较高的EFS、DFS和OS,维持治疗中加用ATRA可明显降低复发率、提高EFS。
Objective To evaluate the efficacy of AML-XH-99-M3 regimen in the treatment of childhood acute promyelocytic leukemia (M3). Methods A total of 33 children with M3 were enrolled in the AML-XH-99-M3 regimen. Kaplan-Meier method was used for survival analysis. EFS, disease-free survival (DFS) and overall survival OS), all data using SPSS13.0 software statistics. Results Thirty patients (90.9%) had one course of complete remission (CR) in one course and two courses of CR in three cases with a total CR rate of 100%, recurrence in 6 cases (18.2%) and mean recurrence time of 29 (16 ~ 38) months, 2 deaths (6.1%), 7-year EFS and DFS were (73.4 ± 9.4)%, total OS was (91.2 ± 6.0)%, intermittent maintenance therapy with all-trans retinoic acid ATRA and no ATRA were statistically significant (88.9 ± 10.5)% and (62.5 ± 13.6)%, respectively (P <0.05). Conclusion The AML-XH-99-M3 regimen has a good CR rate in pediatric patients with high EFS, DFS and OS. Addition of ATRA during maintenance therapy can significantly reduce the recurrence rate and improve EFS.